Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review

Béreau, Matthieu; Fleury, Vanessa; Bouthour, Walid; Castrioto, Anna; Lhommée, Eugénie; Krack, Paul

doi:10.1016/j.neurol.2018.07.005

Cited by 51 publications

(23 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…28 Clinically, preferential stimulation of D3 receptors is associated with the expression of behavioral addictions or ICDs in PD, as reviewed elsewhere. 1,3 Early pharmacotherapy after PD diagnosis, that is L-Dopa monotherapy vs. L-Dopa-sparing regimens relying on dopamine agonists with or without combination with L-Dopa, determine the motor and neuropsychiatric symptom profiles months and years from treatment choice. 29 While motor symptoms, dyskinesias, and motor fluctuations have been repeatedly compared between the two strategies, neuropsychiatric endpoints were not systematically studied.…”

Section: The Role Of Pharmacotherapy and The Receptor Profilementioning

confidence: 99%

“…Moreover, there is a role of the L-Dopa dosage in motor sensitization. 3,17,30 As such, the ELLDOPA study showed that dyskinesias occur after a delay of 40 weeks following administration of a stable dosage of L-Dopa, but more often with higher dosages. 5 Fractioning of L-Dopa is therefore considered for the management of L-Dopa-induced dyskinesia.…”

Section: The Role Of Pharmacotherapy and The Receptor Profilementioning

confidence: 99%

See 1 more Smart Citation

Changing Gears – DBS For Dopaminergic Desensitization in Parkinson's Disease?

Weiß

Volkmann

Fasano

et al. 2021

Annals of Neurology

Self Cite

View full text Add to dashboard Cite

In Parkinson's disease, both motor and neuropsychiatric complications unfold as a consequence of both incremental striatal dopaminergic denervation and intensifying long‐term dopaminergic treatment. Together, this leads to ‘dopaminergic sensitization’ steadily increasing motor and behavioral responses to dopaminergic medication that result in the detrimental sequalae of long‐term dopaminergic treatment. We review the clinical presentations of ‘dopaminergic sensitization’, including rebound off and dyskinesia in the motor domain, and neuropsychiatric fluctuations and behavioral addictions with impulse control disorders and dopamine dysregulation syndrome in the neuropsychiatric domain. We summarize state‐of‐the‐art deep brain stimulation, and show that STN‐DBS allows dopaminergic medication to be tapered, thus supporting dopaminergic desensitization. In this framework, we develop our integrated debatable viewpoint of “changing gears”, that is we suggest rethinking earlier use of subthalamic nucleus deep brain stimulation, when the first clinical signs of dopaminergic motor or neuropsychiatric complications emerge over the steadily progressive disease course. In this sense, subthalamic deep brain stimulation may help reduce longitudinal motor and neuropsychiatric symptom expression – importantly, not by neuroprotection but by supporting dopaminergic desensitization through postoperative medication reduction. Therefore, we suggest considering STN‐DBS early enough before patients encounter potentially irreversible psychosocial consequences of dopaminergic complications, but importantly not before a patient shows first clinical signs of dopaminergic complications. We propose to consider neuropsychiatric dopaminergic complications as a new inclusion criterion in addition to established motor criteria, but this concept will require validation in future clinical trials. ANN NEUROL 2021;90:699–710

show abstract

Section: The Role Of Pharmacotherapy and The Receptor Profilementioning

confidence: 99%

Section: The Role Of Pharmacotherapy and The Receptor Profilementioning

confidence: 99%

Changing Gears – DBS For Dopaminergic Desensitization in Parkinson's Disease?

Weiß

Volkmann

Fasano

et al. 2021

Annals of Neurology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Dopamine dysregulation syndrome refers to the compulsive (mis)use of dopaminergic therapy. The combination of dopamine replacement therapy, coupled with predisposing individual risk factors and Parkinson's disease pathology, yields an addictive syndrome (Béreau 2018). This manifests as mood fluctuations and addictive behaviour.…”

Section: Dopamine Dysregulation Syndromementioning

confidence: 99%

Neuropsychiatric symptoms in Parkinson's disease: aetiology, diagnosis and treatment

et al. 2020

View full text Add to dashboard Cite

SUMMARY Historically, Parkinson's disease was viewed as a motor disorder and it is only in recent years that the spectrum of non-motor disorders associated with the condition has been fully recognised. There is a broad scope of neuropsychiatric manifestations, including depression, anxiety, apathy, psychosis and cognitive impairment. Patients are more predisposed to delirium, and Parkinson's disease treatments give rise to specific syndromes, including impulse control disorders, dopamine agonist withdrawal syndrome and dopamine dysregulation syndrome. This article gives a broad overview of the spectrum of these conditions, describes the association with severity of Parkinson's disease and the degree to which dopaminergic degeneration and/or treatment influence symptoms. We highlight useful assessment scales that inform diagnosis and current treatment strategies to ameliorate these troublesome symptoms, which frequently negatively affect quality of life.

show abstract

“…Impulse control disorder-linked hypersexuality complicated by disseminated gonococcal infection in a patient with Parkinson's disease § Dopaminergic drugs (DD), especially dopamine agonists can induce impulsive and compulsive behavior (ICB) including hypersexuality in patients affected with Parkinson's disease (PD) [1][2][3]. We report a patient with PD treated with DD who experienced ICB, especially hypersexuality leading to disseminated gonococcal infection (DGI), one type of sexually transmitted infection (STI).…”

mentioning

confidence: 99%

“…The assessment of the Ardouin Scale of Behavior in Parkinson's Disease (ASBPD) confirmed moderate depressive mood (2/4), marked anxiety (3/4), marked non-motor fluctuations (3/4), as well as hyperdopaminergic behaviors with rupture with anterior state including moderate hypersexuality (2/4), binge eating and dopaminergic drug abuse [4]. Rotigotine doses were subsequently reduced but this was not tolerated because of a dopamine agonist withdrawal syndrome (DAWS) dominated by anxiety and dysphoria and the patient increased the treatment of her own [1][2][3]. She was wheelchair bound during off periods but she refused both deep brain stimulation (DBS) of the subthalamic nucleus (STN) as well as continuous subcutaneous apomorphine infusion.…”

mentioning

confidence: 99%